Details of Disease

Disease Name

Esophageal disorder

esophageal ulcer; oesophagus disease or disorder; oesophagus disease; esophagus disease or disorder; esophagus disease; esophageal disorder; disorder of oesophagus; disorder of esophagus; disease or disorder of oesophagus; disease or disorder of esophagus; disease of oesophagus; disease of esophagus

Definition

A non-neoplastic or neoplastic disorder that affects the esophagus. Representative examples of non-neoplastic disorders include esophagitis and esophageal ulcer. Representative examples of neoplastic disorders include carcinomas, lymphomas, and melanomas.

Disease Hierarchy

DISWD40R: Disease

DIS7JDYJ: Gastrointestinal disease

:

DIS5L3HQ: Esophageal disorder

Disease Identifiers

MONDO ID

MONDO_0003749

MESH ID

D004935

UMLS CUI

C0014852

MedGen ID

8693

SNOMED CT ID

37657006

General Information of Disease (ID: DIS5L3HQ)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
Erlotinib	DMCMBHA	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
IL18RAP	TTZUJVE	Strong	Genetic Variation	[3]
TRPV1	TTMI6F5	Definitive	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AGA	OTNWT1WB	Limited	Biomarker	[5]
DHTKD1	OTDQLSNT	Limited	Genetic Variation	[6]
------------------------------------------------------------------------------------

References

1	Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020 Oct 7;5(1):229.
2	Erlotinib FDA Label
3	Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma.Am J Gastroenterol. 2012 Sep;107(9):1331-41. doi: 10.1038/ajg.2012.134. Epub 2012 Jun 5.
4	Influence of intra-oesophageal capsaicin instillation on heartburn induction and oesophageal sensitivity in man.Neurogastroenterol Motil. 2009 Oct;21(10):1032-e82. doi: 10.1111/j.1365-2982.2009.01332.x. Epub 2009 Jun 30.
5	Functional Lumen Imaging Probe for the Management of Esophageal Disorders: Expert Review From the Clinical Practice Updates Committee of the AGA Institute.Clin Gastroenterol Hepatol. 2017 Mar;15(3):325-334. doi: 10.1016/j.cgh.2016.10.022.
6	Human 2-Oxoglutarate Dehydrogenase and 2-Oxoadipate Dehydrogenase Both Generate Superoxide/H(2)O(2) in a Side Reaction and Each Could Contribute to Oxidative Stress in Mitochondria.Neurochem Res. 2019 Oct;44(10):2325-2335. doi: 10.1007/s11064-019-02765-w. Epub 2019 Mar 7.